M1 muscarinic receptor Inhibitors
1 drugsAbout M1 muscarinic receptor
The M1 muscarinic receptor, also known as the cholinergic receptor muscarinic 1, binds acetylcholine and triggers intracellular signaling, playing a crucial role in the central and peripheral nervous systems.
While there is currently no genetic evidence directly linking the M1 muscarinic receptor to specific diseases, its involvement in cognitive function, gastric acid secretion, and smooth muscle contraction makes it a potential therapeutic target.
Currently, one FDA-approved drug, darifenacin, targets the M1 muscarinic receptor as a small molecule for an 'other' therapeutic area, approved in 2017 by Macleods Pharms LTD.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Untreated Follicular Lymphoma with only 1 trials.
Top M1 muscarinic receptor Drugs
Only one company, Macleods Pharms LTD, has an approved drug for this target.
Low competition indicates a potential market opportunity for new entrants.
M1 muscarinic receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets M1 muscarinic receptor, using small molecule modality.
The modality landscape suggests an opportunity for novel modalities like antibodies or biologics.
M1 muscarinic receptor Clinical Trials 8 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 2 | 0 | 1 | 1 | 0% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M1 muscarinic receptor Drug Approval Timeline (2017 - 2017)
The first and most recent drug approval was in 2017, with darifenacin.
The approval timeline indicates a potentially unsaturated market with room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 19 clinical trials targeting M1 muscarinic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities